The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Open accessAbstract
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All these effects are consistent with reported roles of APOE4 in inflammation, synaptic impairment, MAPK1 signaling and downstream APP transcription, and early endosomes7,18.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is associated with increased amyloid-β deposition, hyperphosphorylation and aggregation of tau, and accelerated cognitive decline4–7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE4 polymorphism alters the accessibility of the lipid-binding region, which interferes with its cholesterol and lipid transport capacity7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“having the APOE ɛ4 coding mutation(s) increases AD risk 3–15 fold [3]”
From Association of SPI1 haplotypes with altered SPI1 gene expression and Alzheimer’s disease risk (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include PLCG2 P522R rare variant (rs72824905) that provides robust protection against AD (odds ratio ≈ 0.68 [1, 4], comparable to having one APOE2 allele [5]”
From PLCγ2 deficiency compromises systemic immune tolerance and erodes myelin homeostasis while enhancing oxidative metabolism in the mouse brain (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE is the most important risk factor for AD and contributes significantly to the risk of developing several other neurological and nonneurological disorders (18).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the APOE-E4 allele confers a ∼ 3.7 times greater risk than the common variant, APOE-E3, whereas homozygous APOE-E4/E4 carriers have a ∼12-15 times greater risk for developing AD.”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE genotype is the strongest genetic risk factor for AD21, with APOE ε2 conferring protection from disease and APOE ε4 conferring higher risk, compared to the APOE ε3 allele”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, binding to LDLR is required by ApoE to perform its downstream effector function (50–52).”
From Secreted Apoe rewires melanoma cell state vulnerability to ferroptosis (2024) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies have consistently implicated immune-related pathways in AD susceptibility, particularly those involving microglial function [21,22].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When activated, microglia, the resident immune cells of the central nervous system, play a central role in amyloid clearance, synaptic remodeling, and the regulation of inflammatory signaling within the brain [21].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE gene is a known genetic risk factor for neurodegeneration and cardiovascular disease (CVD) [1, 2].”
From Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 exacerbates amyloid pathology by promoting Aβ production and aggregation, and inhibiting Aβ clearance and degradation”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 aggravates the tau pathology via promoting tau phosphorylation, aggregation, propagation, and tau-mediated neurodegeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 mediates and regulates the endocytosis of > 30 ligands, including apolipoprotein E (APOE) and amyloid-β (Aβ) [21–27]”
From LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Compared with APOE3, the APOE4 isoform increases AD risk and theAPOE2 isoform reduces AD risk.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 isoform may affects the development and progression of AD through multiple different pathways in which inflammatory regulation plays crucial role.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“It is known that APOE is predominantly expressed in glial cells, particularly astrocytes and activated microglia, which play central roles in A β accumulation, clearance, and neuroin fl ammation 3,4 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Hyperphosphorylated forms of the microtubule-associated protein tau in neurons is a major hallmark of AD [2, 3].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple cohort studies have demonstrated that the APOE ε4 allele is a major genetic risk factor for AD”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“while the three common isoforms (APOE2, APOE3, and APOE4) influence both amyloid‐β–dependent and independent pathways implicated in AD pathogenesis [1, 2].”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“APOE plays a crucial role in the pathophysiology of AD, particularly in relation to Aβ and tau.43,44”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Cerebrovascular dysfunction has been recognized as a major pathological process of AD”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
The cited source says what the claim attributes to it.
In the citing paper
“with ApoE4-positive cells showing reduced function (Rawat et al., 2019; Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“ApoE4 shows both loss-of-function and gain-of-toxic-function across various AD pathogenesis pathways (Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, cerebral glucose hypometabolism occurs in both the early stage of AD (Christian et al., 2020; Yamazaki et al., 2019) and epilepsy (McDonald et al., 2018; Patel, 2018).”
From APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice (2026) · cites this paper as Yamazaki et al., 2019
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a specific ApoE4 fragment, ApoE4[Δ(166-299)], has previously been found to promote the cellular uptake of extracellular Aβ42 and resulted in increased oxidative stress [28], similar to the effect of L28P.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“APOE is the most significant known risk factor for sporadic Alzheimer’s disease”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“ApoE4 exhibits the strongest receptor binding and is considered a high-risk allele, while ApoE2 exhibits the weakest receptor binding and is considered protective (Yamazaki et al., 2019).”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“APOE also affects tau pathogenesis and tau-mediated neurodegeneration [468].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [468]
In the citing paper
“We also found that LECs isolated from the meninges of 6-month-old 5xFAD mice showed significant changes in the expression of genes involved in processes such as exocytosis, phospholipase D signaling, and response to low-density lipoprotein (Extended Data Fig. 1f–k), suggesting that meningeal Aβ deposition might affect meningeal LECs early on through deleterious processes previously implicated in”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
In the citing paper
“In fact, 39 AD-associated genes were found within the 10th percentile of highly expressed genes in meningeal LECs, including Apoe, which is intrinsically linked to altered risk for late onset AD15,31 and was one of the few highly expressed genes found at the intersection between all three cell types (Extended Data Fig. 9o).”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–318 of 318
Garai, K., Verghese, P. B., Baban, B., Holtzman, D. M., & Frieden, C. (2014) · Biochemistry · doi:10.1021/bi5008172 · Cited by 145
Quadri, M., Mandemakers, W., Grochowska, M. M., Masius, R., Geut, H., Fabrizio, E., Breedveld, G. J., Kuipers, D., Minneboo, M., Vergouw, L. J. M., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30179-0 · Cited by 143
Association of APOE with tau-tangle pathology with and without β-amyloid
Farfel, J. M., Yu, L., Jager, P. L. D., Schneider, J. A., & Bennett, D. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.011 · Cited by 142
Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism
Puschmann, A., Fiesel, F. C., Caulfield, T. R., Hudec, R., Ando, M., Fričová, D., Hou, X., Ogaki, K., Heckman, M. G., James, E. D., et al. (2016) · Brain · doi:10.1093/brain/aww261 · Cited by 141
Self-citationThe endosomal-lysosomal pathway is dysregulated by APOE4 expression in vivo
Nuriel, T., Peng, K. Y., Ashok, A., Dillman, A. A., Figueroa, H. Y., Apuzzo, J., Ambat, J., Levy, E., Cookson, M. R., Mathews, P. M., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00702 · Cited by 140
The genetic landscape of Alzheimer disease
Carmona, S., Hardy, J., & Guerreiro, R. J. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64076-5.00026-0 · Cited by 140
Fryer, J. D., DeMattos, R. B., McCormick, L. M., O'Dell, M. A., Spinner, M. L., Bales, K. R., Paul, S. M., Sullivan, P. M., Parsadanian, M., Bu, G., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502143200 · Cited by 139
Self-citationAPOE ε2 is associated with increased tau pathology in primary tauopathy
Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Linares, C., Kurti, A., Knight, J. A., Heckman, M. G., Diehl, N. N., Shinohara, M., Martens, Y. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06783-0 · Cited by 139
Self-citationPrice, A. R., Xu, G., Siemienski, Z. B., Smithson, L. A., Borchelt, D. R., Golde, T. E., & Felsenstein, K. M. (2013) · Science · doi:10.1126/science.1234089 · Cited by 138
Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology.
Wang, C., Wilson, W. A., Moore, S. D., Mace, B. E., Maeda, N., Schmechel, D. E., & Sullivan, P. M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.10.013 · Cited by 138
The PDBFINDER database: a summary of PDB, DSSP and HSSP information with added value
Hooft, R. W. W., Sander, C., Scharf, M. E., & Vriend, G. (1996) · Computer applications in the biosciences · doi:10.1093/bioinformatics/12.6.525 · Cited by 138
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene
Boehm-Cagan, A., & Michaelson, D. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5198-13.2014 · Cited by 134
Frieden, C., Wang, H., & Ho, C. M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705080114 · Cited by 134
Genetics of Parkinson's disease: the yield
Spatola, M., & Wider, C. W. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70011-7 · Cited by 133
Veeraraghavalu, K., Zhang, C., Miller, S., Hefendehl, J. K., Rajapaksha, T. W., Ulrich, J., Jucker, M., Holtzman, D. M., Tanzi, R. E., Vassar, R., et al. (2013) · Science · doi:10.1126/science.1235505 · Cited by 133
Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132
APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis
Rannikmäe, K., Kalaria, R. N., Greenberg, S. M., Chui, H. C., Schmitt, F. A., Samarasekera, N., Salman, R. A., & Sudlow, C. L. M. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306485 · Cited by 131
Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia
Dong, L., Parkin, S., Trakhanov, S. D., Rupp, B., Simmons, T., Arnold, K. S., Newhouse, Y. M., Innerarity, T. L., & Weisgraber, K. H. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0896-718 · Cited by 129
Ji, Z.-S., Dichek, H. L., Miranda, R. D., & Mahley, R. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31285 · Cited by 128
Liao, F., Hori, Y., Hudry, E., Bauer, A. Q., Jiang, H., Mahan, T. E., Lefton, K. B., Zhang, T. J., Dearborn, J. T., Kim, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0646-14.2014 · Cited by 128
In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
Ulrich, J. D., Burchett, J. M., Restivo, J. L., Schuler, D. R., Verghese, P. B., Mahan, T. E., Landreth, G. E., Castellano, J. M., Jiang, H., Cirrito, J. R., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-13 · Cited by 128
Tesseur, I., Lo, A. C., Roberfroid, A., Dietvorst, S., Van Broeck, B., Borgers, M., Gijsen, H., Moechars, D., Mercken, M., Kemp, J., et al. (2013) · Science · doi:10.1126/science.1233937 · Cited by 128
Apolipoprotein E and Dementia in Parkinson Disease: A Meta-analysis
Huang, X., Chen, P., Kaufer, D. I., Tröster, A. I., & Poole, C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.2.189 · Cited by 128
APOE genotype and early β-amyloid accumulation in older adults without dementia
Lim, Y. Y., Mormino, E. C., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., Weiner, M., Aisen, P., Petersen, R., Jack, C. R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004336 · Cited by 125
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia
Karten, B., Campenot, R. B., Vance, D. E., & Vance, J. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508915200 · Cited by 124
Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease
Shinohara, M., Murray, M. E., Frank, R. D., Shinohara, M., DeTure, M., Yamazaki, Y., Tachibana, M., Atagi, Y., Davis, M. D., Liu, C.-C., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1580-y · Cited by 123
Self-citationShinohara, M., Sato, N., Kurinami, H., Takeuchi, D., Takeda, S., Shimamura, M., Yamashita, T., Uchiyama, Y., Rakugi, H., & Morishita, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102277 · Cited by 122
Accumulation of intraneuronal Aβ correlates with ApoE4 genotype
Christensen, D. Z., Schneider-Axmann, T., Lucassen, P. J., Bayer, T. A., & Wirths, O. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0666-1 · Cited by 120
Halliday, M. R., Pomara, N., Sagare, A. P., Mack, W. J., Frangione, B., & Zlokovic, B. V. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3841 · Cited by 119
Fitz, N. F., Cronican, A. A., Saleem, M., Fauq, A. H., Chapman, R., Lefterov, I., & Koldamova, R. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1937-12.2012 · Cited by 119
Liraz, O., Boehm-Cagan, A., & Michaelson, D. M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-16 · Cited by 118
Robert, J., Button, E. B., Yuen, B., Gilmour, M., Kang, K., Bahrabadi, A., Stukas, S. K., Zhao, W., Kulić, I., & Wellington, C. L. (2017) · eLife · doi:10.7554/elife.29595 · Cited by 118
Cerebral glucose metabolism in patients with AD and different APOE genotypes
Drzezga, A., Riemenschneider, M., Strassner, B., Grimmer, T., Peller, M., Knoll, A., Wagenpfeil, S., Minoshima, S., Schwaiger, M., & Kurz, A. (2005) · Neurology · doi:10.1212/01.wnl.0000148478.39691.d3 · Cited by 116
Lane-Donovan, C., Wong, W. M., Durakoglugil, M. S., Wasser, C. R., Jiang, S., Xian, X., & Herz, J. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1054-16.2016 · Cited by 115
Insulin resistance and AD—extending the translational path
Craft, S. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.112 · Cited by 113
Brodbeck, J., McGuire, J., Liu, Z., Meyer-Franke, A., Balestra, M. E., Jeong, D.-E., Pleiss, M., McComas, C., Hess, F., Witter, D., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217380 · Cited by 113
APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease
Vélez, J. I., Lopera, F., Sepulveda-Falla, D., Patel, H. R., Johar, A. S., Chuah, A., Tobón, C., Rivera, D., Villegas, A., Cai, Y., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.177 · Cited by 111
APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations
Shinohara, M., Kanekiyo, T., Yang, L., Linthicum, D., Shinohara, M., Fu, Y., Price, L., Frisch‐Daiello, J. L., Han, X., Fryer, J. D., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24628 · Cited by 111
Self-citationEffect of Apolipoprotein E Genotype and Diet on Apolipoprotein E Lipidation and Amyloid Peptides
Hanson, A. J., Bayer-Carter, J. L., Green, P. S., Montine, T. J., Wilkinson, C. W., Baker, L. D., Watson, G. S., Bonner, L. M., Callaghan, M., Leverenz, J. B., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.396 · Cited by 110
Sex-specific genetic predictors of Alzheimer’s disease biomarkers
(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetics Consortium (ADGC), Dumitrescu, L., Barnes, L. L., Thambisetty, M., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1881-4 · Cited by 110
Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease
Sorbi, S., Nacmias, B., Forleo, P., Piacentini, S., Latorraca, S., & Amaducci, L. A. (1995) · Annals of Neurology · doi:10.1002/ana.410380120 · Cited by 109
Caulfield, T. R., Fiesel, F. C., Moussaud-Lamodière, E. L., Dourado, D. F. A. R., Flores, S. C., & Springer, W. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003935 · Cited by 109
Self-citationZhao, L., Gottesdiener, A. J., Parmar, M., Li, M., Kaminsky, S. M., Chiuchiolo, M. J., Sondhi, D., Sullivan, P. M., Holtzman, D. M., Crystal, R. G., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.020 · Cited by 107
The effects of ABCA1 on cholesterol efflux and Aβ levels in vitro and in vivo
Burns, M. P., Vardanian, L., Pajoohesh‐Ganji, A., Wang, L., Cooper, M., Harris, D. C., Duff, K., & Rebeck, G. W. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03925.x · Cited by 106
A large study reveals no association between APOE and Parkinson's disease
Federoff, M., Jimenez‐Rolando, B., Nalls, M. A., & Singleton, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.02.002 · Cited by 106
Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice
Cao, D., Fukuchi, K.-I., Wan, H., Kim, H., & Li, L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.011 · Cited by 106
Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers
Caselli, R. J., Dueck, A. C., Locke, D. E. C., Hoffman‐Snyder, C. R., Woodruff, B. K., Rapcsak, S. Z., & Reiman, E. M. (2011) · Neurology · doi:10.1212/wnl.0b013e3182167147 · Cited by 105
Keene, C. D., Cudaback, E., Li, X., Montine, K. S., & Montine, T. J. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.08.002 · Cited by 103
Stocker, H. R., Möllers, T., Perna, L., & Brenner, H. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0221-8 · Cited by 102
Premorbid effects of APOE on synaptic proteins in human temporal neocortex
Love, S., Siew, L. K., Dawbarn, D., Wilcock, G. K., Ben‐Shlomo, Y., & Allen, S. J. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.008 · Cited by 101
Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein.
Wilson, C., Mau, T., Weisgraber, K. H., Wardell, M. R., Mahley, R. W., & Agard, D. A. (1994) · Structure · doi:10.1016/s0969-2126(00)00072-1 · Cited by 100
Interaction of the N-Terminal Domain of Apolipoprotein E4 with Heparin
Dong, J., Peters-Libeu, C. A., Weisgraber, K. H., Segelke, B. W., Rupp, B., Capila, I., Hernáiz, M. J., LeBrun, L. A., & Linhardt, R. J. (2001) · Biochemistry · doi:10.1021/bi002417n · Cited by 99
Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43
Wennberg, A. M. V., Tosakulwong, N., Lesnick, T. G., Murray, M. E., Whitwell, J. L., Liesinger, A. M., Petrucelli, L., Boeve, B. F., Parisi, J. E., Knopman, D. S., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3139 · Cited by 96
Hippocampal atrophy rates and CSF biomarkers in elderly APOE 2 normal subjects
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S. T., Jack, C. R., Aisen, P. S., Petersen, R. C., Weiner, M. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4d1 · Cited by 94
Mak, A. C. Y., Pullinger, C. R., Tang, L. F., Wong, J. S., Deo, R. C., Schwarz, J.-M., Gugliucci, A., Movsesyan, I., Ishida, B. Y., Chu, C., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2011 · Cited by 94
The ApoE receptors Vldlr and Apoer2 in central nervous system function and disease
Lane-Donovan, C., & Herz, J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075507 · Cited by 94
Kuszczyk, M. A., Sanchez, S., Pankiewicz, J., Kim, J., Duszczyk, M., Guridi, M., Asuni, A. A., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.034 · Cited by 89
Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo
Tai, L. M., Koster, K. P., Luo, J., Lee, S. H., Wang, Y.-T., Collins, N. C., Ben Aissa, M., Thatcher, G. R. J., & LaDu, M. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.600833 · Cited by 89
Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation
Ekblad, L. L., Johansson, J. J., Helin, S., Viitanen, M. H., Laine, H. K., Puukka, P. J., Jula, A., & Rinne, J. O. (2018) · Neurology · doi:10.1212/wnl.0000000000005214 · Cited by 89
Mattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.009 · Cited by 88
Vitek, M. P., Christensen, D. J., Wilcock, D. M., Davis, J., Nostrand, W. E. V., Li, F. Q., & Colton, C. A. (2012) · Neurodegenerative Diseases · doi:10.1159/000334914 · Cited by 84
Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease
Mosconi, L. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.014993 · Cited by 83
Yassine, H. N., Feng, Q., Chiang, J., Petrosspour, L. M., Fonteh, A. N., Chui, H. C., & Harrington, M. G. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002886 · Cited by 80
How can elderly apolipoprotein E ε4 carriers remain free from dementia?
Ferrari, C., Xu, W., Wang, H., Winblad, B. G., Sorbi, S., Qiu, C., & Fratiglioni, L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.003 · Cited by 79
APOE and other loci affect age‐at‐onset in Alzheimer's disease families with PS2 mutation
Wijsman, E. M., Daw, E. W., Yu, X., Steinbart, E. J., Nochlin, D., Bird, T. D., & Schellenberg, G. D. (2005) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30087 · Cited by 79
Genetic variants of ApoE and ApoER2 differentially modulate endothelial function
Ulrich, V., Konaniah, E. S., Herz, J., Gerard, R. D., Jung, E.-J., Yuhanna, I. S., Ahmed, M., Hui, D. Y., Mineo, C., & Shaul, P. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402106111 · Cited by 77
Brodeur, J., Thériault, C., Lessard-Beaudoin, M., Marcil, A., Dahan, S., & Lavoie, C. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-31 · Cited by 77
Lalloyer, F., Pedersen, T. Å., Gross, B. S., Lestavel, S., Yous, S., Vallez, E., Gustafsson, J.-Α., Mandrup, S., Fiévet, C., Staels, B., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.189506 · Cited by 76
Apolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid
Heinsinger, N. M., Gachechiladze, M. A., & Rebeck, G. W. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw067 · Cited by 74
Genetics of Vascular Dementia: Systematic Review and Meta-Analysis
Sun, J., Tan, L., Wang, H.-F., Tan, M.-S., Tan, L., Li, J., Xu, W., Zhu, X.-C., Jiang, T., & Yu, J.-T. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143102 · Cited by 74
Ghosal, K., Haag, M., Verghese, P. B., West, T., Veenstra, T., Braunstein, J. B., Bateman, R. J., Holtzman, D. M., & Landreth, G. E. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.001 · Cited by 73
Katsouri, L., & Georgopoulos, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021880 · Cited by 72
Sundermann, E. E., Tran, M., Maki, P. M., Bondi, M. W., & Initiative, A. D. N. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.06.004 · Cited by 72
ApoE Regulates the Development of Adult Newborn Hippocampal Neurons
Tensaouti, Y., Stephanz, E. P., Yu, T., & Kernie, S. G. (2018) · eNeuro · doi:10.1523/eneuro.0155-18.2018 · Cited by 71
Bertens, D., Knol, D. L., Scheltens, P., Visser, P. J., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.1754 · Cited by 70
Fu, Y., Zhao, J., Atagi, Y., Nielsen, H. M., Liu, C.-C., Zheng, H., Shinohara, M., Kanekiyo, T., & Bu, G. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0099-y · Cited by 69
Self-citationKlein, R. C., Mace, B. E., Moore, S. D., & Sullivan, P. M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.10.027 · Cited by 67
Age‐dependent effects of APOE ε4 in preclinical Alzheimer's disease
Bonham, L. W., Geier, E. G., Fan, C. C., Leong, J. K., Besser, L. M., Kukull, W. A., Kornak, J., Andreassen, O. A., Schellenberg, G. D., Rosen, H. J., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.333 · Cited by 65
Relative effect of APOE ε4 on neuroimaging biomarker changes across the lifespan
Gonneaud, J., Arenaza‐Urquijo, E. M., Fouquet, M., Perrotin, A., Fradin, S., Sayette, V. D. L., Eustache, F., & Chételat, G. (2016) · Neurology · doi:10.1212/wnl.0000000000003234 · Cited by 65
Sudre, C. H., Cardoso, M. J., Frost, C. D., Barnes, J., Barkhof, F., Fox, N. C., & Sebastien Ourselin, A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.014 · Cited by 62
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60
Motion of transfer RNA from the A/T state into the A‐site using docking and simulations
Caulfield, T. R., & Devkota, B. (2012) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24131 · Cited by 58
Self-citationPankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 57
Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1
Tachibana, M., Shinohara, M., Yamazaki, Y., Liu, C., Rogers, J. T., Bu, G., & Kanekiyo, T. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.12.003 · Cited by 57
Self-citationJohnson, L. A., Torres, E. R., Weber Boutros, S., Patel, E., Akinyeke, T., Alkayed, N. J., & Raber, J. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17746186 · Cited by 56
Structure of the Minimal Interface Between ApoE and LRP
Guttman, M., Prieto, J. H., Handel, T. M., Domaille, P. J., & Komives, E. A. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.022 · Cited by 56
A subset of senile dementia with high incidence of the apolipoprotein E ϵ2 allele
Ikeda, K., Akiyama, H., Arai, T., Sahara, N., Mori, H., Usami, M., Sakata, M., Mizutani, T., Wakabayashi, K., & Takahashi, H. (1997) · Annals of Neurology · doi:10.1002/ana.410410522 · Cited by 55
Clinical phenotype, atrophy, and small vessel disease in APOE ε2 carriers with Alzheimer disease
Groot, C., Sudre, C. H., Barkhof, F., Teunissen, C. E., van Berckel, B. N. M., Seo, S. W., Sebastien Ourselin, A., Scheltens, P., Cardoso, M. J., van der Flier, W. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006503 · Cited by 54
Baker-Nigh, A. T., Mawuenyega, K. G., Bollinger, J. G., Ovod, V., Kasten, T., Franklin, E. E., Liao, F., Jiang, H., Holtzman, D., Cairns, N. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721779 · Cited by 54
Ghosal, K., Stathopoulos, A. M., Thomas, D. G., Phenis, D., Vitek, M. P., & Pimplikar, S. W. (2012) · Neurodegenerative Diseases · doi:10.1159/000341299 · Cited by 53
Apolipoprotein E υ4 Allele Frequency in Vascular Dementia
Davidson, Y. S., Gibbons, L., Purandare, N. B., Byrne, E. J., Hardicre, J., Wren, J., Payton, A., Pendleton, N., Horan, M. A., Burns, A. S., et al. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000092960 · Cited by 53
A Tale of Two Genes: Microglial Apoe and Trem2
Pimenova, A. A., Marcora, E. M., & Goate, A. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.015 · Cited by 52
杉山, 拓., Kumagai, H., Morikawa, Y., Wada, Y., Sugiyama, A., Yasuda, K., Yokoi, N., Tamura, S., Kojima, T., Nosaka, T., et al. (2000) · Biochemistry · doi:10.1021/bi001583s · Cited by 51
APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease
Tropea, T. F., Xie, S. X., Rick, J. H., Chahine, L. M., Dahodwala, N. A., Doshi, J. J., Davatzikos, C. A., Shaw, L. M. J., Deerlin, V. M. V., Trojanowski, J. Q., et al. (2017) · Movement Disorders · doi:10.1002/mds.27204 · Cited by 51
In Vivo and In Vitro Effects of an Apolipoprotein E Mimetic Peptide on Amyloid-β Pathology
Handattu, S. P., Monroe, C. E., Nayyar, G., Palgunachari, M. N., Kadish, I., van Groen, T., Anantharamaiah, G. M., & Garber, D. W. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122377 · Cited by 50
Murphy, K. R., Landau, S. M., Choudhury, K. R., Hostage, C. A., Shpanskaya, K. S., Sair, H. I., Petrella, J. R., Wong, T. Z., & Doraiswamy, P. M. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.048 · Cited by 50
Activation of the E3 ubiquitin ligase Parkin
Caulfield, T. R., Fiesel, F. C., & Springer, W. (2015) · Biochemical Society Transactions · doi:10.1042/bst20140321 · Cited by 49
Self-citationSegelke, B. W., Forstner, M., Knapp, M., Trakhanov, S. D., Parkin, S., Newhouse, Y. M., Bellamy, H. D., Weisgraber, K. H., & Rupp, B. (2000) · Protein Science · doi:10.1110/ps.9.5.886 · Cited by 47
Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load
Grothe, M. J., Villeneuve, S., Dyrba, M., Bartrés‐Faz, D., Wirth, M., Initiative, A. D. N., Initiative, A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003585 · Cited by 47
Geijselaers, S. L. C., Aalten, P., Ramakers, I. H. G. B., Deyn, P. P. D., Heijboer, A. C., Koek, H. L., Olde-Rikkert, M. G. M., Papma, J. M., Reesink, F. E., Smits, L. L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170522 · Cited by 46
APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy
Tsuboi, Y., Josephs, K. A., Cookson, N., & Dickson, D. W. (2003) · Neurology · doi:10.1212/01.wnl.0000044340.37138.a9 · Cited by 45
Nielsen, H. M., Chen, K., Lee, W., Chen, Y., Bauer, R. J., III, Reiman, E. M., Caselli, R. J., & Bu, G. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0231-9 · Cited by 44
Self-citationApolipoprotein E element 4 allele frequency is not increased in progressive supranuclear palsy
Tabaton, M., Rolleri, M., Masturzo, P., Cammarata, S., Angelini, G., Hansen, L. A., Saitoh, T., Petersen, R. B., Perry, G. L., Richey, P. L., et al. (1995) · Neurology · doi:10.1212/wnl.45.9.1764 · Cited by 40
Concerning the structure of apoE
Frieden, C., & Garai, K. (2013) · Protein Science · doi:10.1002/pro.2379 · Cited by 39
Sweet, R. A., MacDonald, M. L., Kirkwood, C. M., Ding, Y., Schempf, T. A., Jones-Laughner, J., Kofler, J., Ikonomović, M. D., López, O. L., Garver, M. E., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.056580 · Cited by 36
Montine, T. J., & Montine, K. S. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150656 · Cited by 34
Reduced neuronal signaling in the ageing apolipoprotein-E4 targeted replacement female mice
Yong, S. M., Lim, M., Low, C., & Wong, B. (2014) · Scientific Reports · doi:10.1038/srep06580 · Cited by 33
Apo E: The role of conserved residues in defining function
Frieden, C. (2015) · Protein Science · doi:10.1002/pro.2597 · Cited by 29
Zubenko, G. S., Stiffler, J. S., Hughes, H. B., Hurtt, M. R., & Kaplan, B. B. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19980207)81:1 · Cited by 29
Kayode, O., Wang, R., Pendlebury, D. F., Cohen, I., Henin, R. D., Hockla, A., Soares, A. S., Papo, N., Caulfield, T. R., & Radisky, E. S. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.758417 · Cited by 27
Self-citationApoE: In Vitro Studies of a Small Molecule Effector
Mondal, T., Wang, H., DeKoster, G. T., Baban, B. A., Gross, M. L., & Frieden, C. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00324 · Cited by 25
Kara, E., Marks, J. D., Fan, Z., Klickstein, J. A., Roe, A. D., Krogh, K. A., Wegmann, S., Maesako, M., Luo, C. C., Mylvaganam, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.784264 · Cited by 23
Finan, G. M., Realubit, R. B., Chung, S., Lütjohann, D., Wang, N., Cirrito, J. R., Karan, C., & Kim, T. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.10.015 · Cited by 22
Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer’s Disease
Morris, J. K., Uy, R. A. Z., Vidoni, E. D., Wilkins, H., Archer, A. E., Thyfault, J. P., Miles, J. M., & Burns, J. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170148 · Cited by 20
Pardo, J. V., Lee, J. T., & Initiative, A. D. N. (2018) · eNeuro · doi:10.1523/eneuro.0396-17.2018 · Cited by 8
Richter, J. E., Robles, H. G., Mauricio, E. A., Mohammad, A. N., Atwal, P. S., & Caulfield, T. R. (2018) · Human Genome Variation · doi:10.1038/hgv.2018.16 · Cited by 8
Self-citationHanagasi, H. A., Cantürk, P. U., Bılgıç, B., Gurvit, H. I., & Emre, M. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.584 · Cited by 6
Flagged first, then by citations
Cited by
Sorted by citations
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“Compared with APOE3, the APOE4 isoform increases AD risk and theAPOE2 isoform reduces AD risk.(166) A single amino acid difference between APOE3 and APOE4 leads to the changing of protein conformation which affects the binding of APOE with its receptors, lipids, and Aβ.”
BackgroundMolecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Function and therapeutic value of astrocytes in neurological diseases
Lee, H.-G., Wheeler, M. A., & Quintana, F. J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00390-x · Cited by 662
Lipid droplet biogenesis and functions in health and disease
Zadoorian, A., Du, X., & Yang, H. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00845-0 · Cited by 617
Metadata
- Authors
- Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G.
- Affiliations
- Mayo Clinic in Florida (US)
- Corresponding author
- Bu, Guojun
- Venue
- Nature Reviews Neurology
- Published
- 2019-07-31
- Volume
- 15
- Issue
- 9
- Pages
- 501-518
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC7055192
- OpenAlex
- W2965401191
- Cited by
- 1,425
- References
- 318
- Citations by year
- 2026: 191 · 2025: 259 · 2024: 233 · 2023: 242 · 2022: 200 · 2021: 172 · 2020: 124 · 2019: 4
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (RF1AG051504, R01AG027924, R37AG027924, RF1AG057181, RF1AG046205, R01AG035355)
- National Institute of Neurological Disorders and Stroke (P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, APOE polymorphism, amyloid-beta, tau pathology, neurodegeneration, microglial activation, lipid transport, synaptic plasticity, glucose metabolism, cerebrovascular function, precision medicine
- MeSH terms
- Alzheimer Disease, Apolipoproteins E, Brain, Humans, Polymorphism, Genetic, Amyloid beta-Peptides, Genetic Predisposition to Disease, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
